| Literature DB >> 29498581 |
Shoko Merrit Yamada1, Yusuke Tomita1, Soichiro Shibui1, Mikiko Takahashi2, Masashi Kawamoto2, Sumihito Nobusawa3, Junko Hirato4.
Abstract
Astroblastoma is a rare tumor that is thought to occur exclusively in the cerebrum. To the authors' knowledge, no cases of spinal cord astroblastoma have been reported. A 20-year-old woman presented with numbness in her legs. MRI demonstrated a 2-cm intramedullary enhancing lesion in the spinal cord at the T-1 level. The patient declined to undergo resection of the tumor because she was able to walk unassisted; however, she returned for surgery 1 month later because she had developed paraplegia with bladder and rectal dysfunction, and MRI showed enlargement of the tumor. Intraoperatively, the border between the tumor and normal tissue was poorly defined. Biopsy samples were obtained for histopathological examinations, and a diagnosis of astroblastoma with a Ki-67 index of 5% was made. Considering the rapid tumor growth on MRI and remarkable deterioration in her symptoms, the patient was treated with a combination of radiation therapy, temozolomide (TMZ), and bevacizumab. After completion of the combined treatment, she was able to move her toes, and oral TMZ and bevacizumab injections were continued. Six months later, definite tumor shrinkage was identified on MRI, and the patient was able to stand up from a wheelchair without assistance and walk by herself. No therapeutic regimens for residual astroblastoma are established; however, in this case the authors' therapeutic strategy was successful in treating the spinal cord astroblastoma.Entities:
Keywords: EMA = epithelial membrane antigen; FISH = fluorescence in situ hybridization; TMZ = temozolomide; astroblastoma; bevacizumab; oncology; radiation; spinal cord; temozolomide
Mesh:
Year: 2018 PMID: 29498581 DOI: 10.3171/2017.9.SPINE161302
Source DB: PubMed Journal: J Neurosurg Spine ISSN: 1547-5646